Healio: Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study

Dr. Eric Lawitz, clinical professor of medicine in the Division of Gastroenterology, is featured in this Q&A about a new drug being evaluated for nonalcoholic steatohepatitis. Dr. Lawitz led the phase 2 study with promising results.

Read the full story.



Share This Article!
Article Categories: In the News